Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...
officially launched in the U.S. with a high-profile delegation of Indian business leaders engaging in exclusive, closed-door discussions with members of the incoming U.S. administration and key ...